By Mihika Sharma and Akanksha Khushi
April 26 (Reuters) – Sun Pharmaceutical Industries will acquire Organon & Co in an all‑cash deal, valuing the U.S. drugmaker at about $11.75 billion including debt, in one of India’s biggest outbound deals.
The acquisition would help Sun Pharma further expand its women’s health portfolio with access to Organon’s portfolio of more than 70 products across women’s health and general medicines, commercialized across 140 countries.
With the acquisition of Organon, spun off from Merck in 2021, Sun Pharma also aims to grow its innovative medicines portfolio and enter into biosimilars.
As part of the deal, Sun Pharma will buy all the outstanding shares of Organon for $14.00 per share, the companies said in a joint statement, representing a premium of more than 24% to the stock’s last close on Friday.
“Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform,” said Dilip Shanghvi, executive chairman of Sun Pharma.
Sun Pharma, valued at more than $40 billion, plans to fund the acquisition through a combination of available cash resources and committed financing from banks.
The generic drugmaker has been focusing on strengthening its portfolio in dermatology, oncology, and obesity therapy, as it grapples with declining sales in the United States where shifting tariff policies under President Donald Trump continue to weigh on profit margins.
Among Indian drugmakers, Sun is one of the most exposed to the U.S. market. To mitigate the situation, the company has said that it is open to expanding its manufacturing presence in the U.S. in the future.
(Reporting by Mihika Sharma and Akanksha Khushi in Bengaluru; Editing by Subhranshu Sahu)
